Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

353.20GBp
5:14pm IST
Change (% chg)

62.00 (+21.29%)
Prev Close
291.20
Open
360.00
Day's High
391.40
Day's Low
351.20
Volume
4,579,658
Avg. Vol
2,813,262
52-wk High
504.60
52-wk Low
238.00

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 48.23 30.93 32.76
EPS (TTM): 0.07 -- --
ROI: 25.75 15.07 14.61
ROE: -- 16.60 16.34

Indivior's shares soar 33 percent after U.S. court blocks sale of rival generic

Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

2:54pm IST

UPDATE 1-Indivior's shares soar 33 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

2:51pm IST

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

12:46pm IST

UPDATE 1-UK Stocks-Factors to watch on July 16

July 16 Britain's FTSE 100 futures were flat ahead of the cash market open on Monday.

12:07pm IST

UK Stocks-Factors to watch on July 16

July 16 Britain's FTSE 100 index is seen opening 10 points lower on Monday, according to financial bookmakers. * INDIVIOR: A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday. * ROLLS-ROYCE: British jet engine maker Rolls-Royce has designed a propulsion system for a flying tax

11:01am IST

BUZZ-India's Dr.Reddy's Laboratories plunges; Indivior wins preliminary injunction against co

** Dr.Reddy's Laboratories Ltd falls as much as 10.8 pct to a five-week low of 2,069.95 rupees

10:10am IST

Morning News Call - India, July 16

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_07162018.pdf If you would like to receive this newsletter via email, please register at: https://forms.thomsonreuters.com/india-morning/ FACTORS TO WATCH 10:00 am: Interim Finance Minister Piyush Goyal at an event in New Delhi. 12:00 pm: Government to release June wholesale price inflation data in New Delhi. LIVECHAT-MARKETS FOCUS

9:08am IST

Indivior wins preliminary injunction against generic rival

A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

14 Jul 2018

Indivior wins preliminary injunction against generic rival

A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

14 Jul 2018

UPDATE 1-Indivior wins preliminary injunction against generic rival

July 13 A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

14 Jul 2018

Earnings vs. Estimates